Quality of Life and Related Dimensions in Cancer Patients Treated with Mistletoe Extract (Iscador): A Meta-Analysis

Table 1

Overview on identified clinical studies/strata.

Ref.	Year	Number of patients		Tumor localization	Study design of all studies				QoL instrument	Outcome
		Iscador	Control		control	design	matching	JADAD score		SMD	STE
[24]*	2001	20	10	Breast	PLG	Rand	—	1	Spitzer QoL Index	1.71	0.39
[25]*	1991	114	113	Lung	PLG	Rand	—	2	Karnofsky’s Index + additional items	0.32	0.15
[26, 27]	2001	39	39	Multiple	PLG	Rand	MP	2	Self regulation	0.53	0.23
[26, 27]	2001	17	17	Breast	PLG	Rand	MP	2	Self regulation	0.53	0.34
[28]	2006	17	17	Breast	PLG	Rand	MP	2	Self regulation	0.67	0.34
[29]	2006	38	38	Breast	PLG	Rand	MP	2	Self regulation	0.53	0.23
[29]	2006	84	84	Breast	PLG	NR	MP	1	Self regulation	0.34	0.15
[30]	2007	41	41	Ovary	PLG	Rand	MP	2	Self regulation	1.24	0.32
[30]	2007	137	137	Ovary	PLG	NR	MP	1	Self regulation	0.45	0.16
[31]	2007	19	19	Cervix	PLG	Rand	MP	2	Self regulation	0.51	0.32
[31]	2007	102	102	Cervix	PLG	NR	MP	1	Self regulation	0.81	0.14
[32]	2007	22	22	Melanoma	PLG	Rand	MP	2	Self regulation	0.84	0.30
[33]	2008	198	198	Corpus uteri	PLG	NR	MP	0	Self regulation	0.27	0.10
[33]	2008	56	56	Corpus uteri	PLG	Rand	MP	1	Self regulation	0.62	0.19
[34]	2005	33	33	Breast	PLG	Rand	—	2	EORTC-QLQ C30, BR 23	0.59	0.25
[35, 36]	1984	14	—	Kidney	historic	—	—	—	Visual analogue Scale	—	—

PLG: parallel group; Rand: randomization; NR: no randomization; MP: matched pairs; SMD: standardized mean differences; STE: standard error; *placebo/alternative control, and thus not included in the statistical analysis.